Value
4.8/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 4.0 |
| P/S | 9.2 |
| EV/EBITDA | 6.7 |
| Fwd P/E | 3.9 |
| PEG | 3.3 |
- ▸Forward P/E: 30.3x
- ▸PEG: 3.74
VMD · Why this verdict
Why Viemed Healthcare (VMD) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Viemed is posting strong growth - 28% YoY per the engine notes - and ranks as an industry growth leader (growth peer rank 8.28), positioning it as an outlier grower within medical devices. Growth breakdown | Revenue growth should stay above 20% YoY and the growth peer rank should remain in the top quartile over the next 12 months. | →Stable |
| CounterGrowth strength is already reflected in the price near its 52-week high per the bear case, leaving little room for a growth surprise to further re-rate the stock. | ||
The engine's asymmetry gate failed at -1.48, with modeled upside of -22.2% (target already reached) against 15% downside - the risk/reward is unfavorable at the current price near the 52-week high. Reward-to-risk math | Asymmetry ratio should improve toward positive territory (above 0) as either price pulls back or analyst targets rise over the next 12 months. | →Stable |
| CounterFast growers frequently re-rate to new highs and analyst targets get raised after strong quarters, which could quickly flip the asymmetry calculation positive. | ||
Viemed shows excellent cash conversion at 190% FCF/NI and a strong Piotroski F-Score of 7/9, indicating fundamentally sound execution behind the growth story. Quality breakdown | FCF/NI conversion should stay above 100% and the Piotroski score should hold at 7 or better over the next 12 months. | →Stable |
| CounterA Piotroski score can decline quickly if leverage rises or margins compress, and the reported 8.5 debt-to-equity leverage penalty already signals rising balance-sheet risk. | ||
The model applies a leverage penalty (D/E of 8.5, -1.5 score impact) as a named bear case factor, flagging balance-sheet risk despite otherwise strong quality metrics. Bear case | Debt-to-equity should decline from 8.5 toward a more moderate level over the next 12 months as the leverage penalty eases. | →Stable |
| CounterHigh D/E in a growth-stage medtech company financing expansion is common and may not indicate distress if revenue growth of 28% YoY continues to outpace debt service costs. | ||
Insiders sold $347,167 (0.075% of market cap) over the past 90 days across 6 transactions with no offsetting buys, and momentum is overbought (RSI 83) even while the momentum score of 7.1 clears the engine's threshold. Insider transaction read | Insider activity should shift toward net buying or stabilize, and RSI should cool from overbought levels without a break below the 200-day moving average, over the next 12 months. | →Stable |
| CounterAt only 0.075% of market cap, this insider selling is classified MINOR and likely reflects routine diversification rather than a bearish signal on business prospects. | ||
Viemed is posting strong growth - 28% YoY per the engine notes - and ranks as an industry growth leader (growth peer rank 8.28), positioning it as an outlier grower within medical devices.
→StableGrowth breakdown
- Expectation
- Revenue growth should stay above 20% YoY and the growth peer rank should remain in the top quartile over the next 12 months.
CounterGrowth strength is already reflected in the price near its 52-week high per the bear case, leaving little room for a growth surprise to further re-rate the stock.
The engine's asymmetry gate failed at -1.48, with modeled upside of -22.2% (target already reached) against 15% downside - the risk/reward is unfavorable at the current price near the 52-week high.
→StableReward-to-risk math
- Expectation
- Asymmetry ratio should improve toward positive territory (above 0) as either price pulls back or analyst targets rise over the next 12 months.
CounterFast growers frequently re-rate to new highs and analyst targets get raised after strong quarters, which could quickly flip the asymmetry calculation positive.
Viemed shows excellent cash conversion at 190% FCF/NI and a strong Piotroski F-Score of 7/9, indicating fundamentally sound execution behind the growth story.
→StableQuality breakdown
- Expectation
- FCF/NI conversion should stay above 100% and the Piotroski score should hold at 7 or better over the next 12 months.
CounterA Piotroski score can decline quickly if leverage rises or margins compress, and the reported 8.5 debt-to-equity leverage penalty already signals rising balance-sheet risk.
The model applies a leverage penalty (D/E of 8.5, -1.5 score impact) as a named bear case factor, flagging balance-sheet risk despite otherwise strong quality metrics.
→StableBear case
- Expectation
- Debt-to-equity should decline from 8.5 toward a more moderate level over the next 12 months as the leverage penalty eases.
CounterHigh D/E in a growth-stage medtech company financing expansion is common and may not indicate distress if revenue growth of 28% YoY continues to outpace debt service costs.
Insiders sold $347,167 (0.075% of market cap) over the past 90 days across 6 transactions with no offsetting buys, and momentum is overbought (RSI 83) even while the momentum score of 7.1 clears the engine's threshold.
→StableInsider transaction read
- Expectation
- Insider activity should shift toward net buying or stabilize, and RSI should cool from overbought levels without a break below the 200-day moving average, over the next 12 months.
CounterAt only 0.075% of market cap, this insider selling is classified MINOR and likely reflects routine diversification rather than a bearish signal on business prospects.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Viemed pairs industry-leading 28% revenue growth and strong cash conversion with a stock trading near its highs where the engine's asymmetry gate has failed - leverage risk, overbought momentum, and modest insider selling temper an otherwise fundamentally sound growth story.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.6 |
| ROA | 5.5 |
| Gross margin | 7.5 |
| Op margin | 2.5 |
| Net margin | 2.6 |
| Current ratio | 4.7 |
| FCF quality | 10.0 |
| Moat | 7.9 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 190% FCF/NI
- ▸Wide economic moat
- ▸Strong Piotroski F-Score: 8/9
Growth
6.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 9.4 |
| EPS growth | 3.6 |
- ▸Strong growth: 28% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 8.1 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.2 |
- ▸Overbought (RSI 86)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 3.6 |
| erm sentiment | 5.0 |
Insider
5.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
- ▸Modest insider selling — $347,167 (0.075% of mkt cap)
- ▸Institutions accumulating
Peer rank
7.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.7 |
| quality rank | 6.1 |
| growth rank | 8.2 |
- ▸Industry growth leader
- ▸Conservative debt levels
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.5 |
| support resistance | 1.1 |
| 52w position | 9.6 |
Risk (lower is worse)
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.3 |
| days to cover | 8.7 |
| volatility | 4.1 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 6.6 |
| debt equity | 9.7 |
- ▸High IV: 147%
- ▸Above max pain $2
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (6)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.5=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.53
Upside
-23.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $0.5B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.6>=5.5. Top dim: Peer rank at 7.0; weakest: Catalyst at 3.3. No conviction either direction.
The strongest dimensions are Peer rank at 7.0, Momentum at 6.6, and Growth at 6.5; the weakest are Catalyst at 3.3, Technical at 4.1, and Sentiment at 4.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -1.53 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Industry Leading Revenue Growth
Trip ifRevenue growth falls below 15% YoY, down from the current 28%.
- P2Asymmetry Gate Signals Limited Upside
Trip ifAsymmetry ratio rises above 0.5 from the current -1.48, or modeled upside exceeds 10%.
- P3Strong Cash Conversion And Piotroski Score
Trip ifFCF/NI conversion falls below 100% from the current 190%, or Piotroski F-Score drops below 6.
- P4Elevated Leverage Penalty
Trip ifDebt-to-equity ratio rises above 10 from the current 8.5, or the leverage penalty deduction exceeds -3.0.
- P5Modest Insider Selling Amid Overbought Momentum
Trip ifNet insider selling value exceeds $1,000,000 over a rolling 90-day window, nearly tripling the current $347,167.